Tnf-α messenger ribonucleic acid (mrna) in patients with nonalcoholic steatohepatitis

European Cytokine Network

Volumn 23, Issue 3, 2012, Pages 107-111

  Alaaeddine, Nada ^a   Sidaoui, Joseph ^a   Hilal, George ^a   Serhal, Reem ^a   Abedelrahman, Abir ^b   Khoury, Salem ^b  

^a SAINT JOSEPH UNIVERSITY   (Lebanon)

^b UNIVERSITY OF BALAMAND   (Lebanon)

Author keywords

Nonalcoholic steatohepatitis; PCR; RNA; Tumor necrosis factor

Indexed keywords

MESSENGER RNA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA RECEPTOR;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; NONALCOHOLIC FATTY LIVER; NUCLEOTIDE SEQUENCE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY;

ADULT; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; FATTY LIVER; FEMALE; HUMANS; MALE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; RNA, MESSENGER; ROC CURVE; SOLUBILITY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84868124411     PISSN: 11485493     EISSN: None     Source Type: Journal    
DOI: 10.1684/ecn.2012.0313     Document Type: Article

References (38)

1. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980; 55(7): 434-438.
2. Byrne CD, Olufadi R, Bruce KD, Cagampang FR, Ahmed MH. Metabolic disturbances in non-alcoholic fatty liver disease. Clin Sci (Lond) 2009; 116(7): 539-564.
3. Caldwell SH, Oelsner DH, Iezzoni JC, Hespenheide EE, Battle EH, Driscoll CJ. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 1999; 29(3): 664-669.
4. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002; 346(16): 1221-1231.
5. Cortez-Pinto H, Camilo ME. Non-alcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH): diagnosis and clinical course. Best Pract Res Clin Gastroenterol 2004; 18(6): 1089-2104.
6. Farrell GC, van Rooyen D, Gan L, Chitturi S. NASH is an Inflammatory Disorder: Pathogenic, Prognostic and Therapeutic Implications. Gut Liver 2012; 6(2): 149-171.
7. Larter CZ, Chitturi S, Heydet D, Farrell GC. A fresh look at NASH pathogenesis. Part 1: the metabolic movers. J Gastroenterol Hepatol 2010; 25(4): 672-690.
8. Kern PA, Saghizadeh M, Ong JM, Bosch RJ, Deem R, Simsolo RB. The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest 1995; 95(5): 2111-2119.
9. Diehl AM. Tumor necrosis factor and its potential role in insulin resistance and nonalcoholic fatty liver disease. Clin Liver Dis 2004; 8(3): 619-638.
10. Hui JM, Hodge A, Farrell GC, Kench JG, Kriketos A, George J. Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology 2004; 40(1): 46-54.
11. Jarrar MH, Baranova A, Collantes R, et al. Adipokines and cytokines in non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2008; 27(5): 412-421.
12. Tomita K, Tamiya G, Ando S, et al. Tumour necrosis factor alpha signalling through activation of Kupffer cells plays an essential role in liver fibrosis of non-alcoholic steatohepatitis in mice. Gut 2006; 55(3): 415-424.
13. Pappo I, Bercovier H, Berry E, Gallilly R, Feigin E, Freund HR. Antitumor necrosis factor antibodies reduce hepatic steatosis during total parenteral nutrition and bowel rest in the rat. J Parenter Enteral Nutr 1995; 19(1): 80-102.
14. Wigg AJ, Roberts-Thomson IC, Dymock RB, McCarthy PJ, Grose RH, Cummins AG. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis. Gut 2001; 48(2): 206-211.
15. Higuchi M, Aggarwal BB, Yeh ET. Activation of CPP32-like proteasein tumor necrosis factor-induced apoptosis is dependent on mitochondrial function. J Clin Invest 1997; 99(7): 1751-1758.
16. Schulze-OsthoffK, Bakker AC,Vanhaesebroeck B, Beyaert R, Jacob WA, Fiers W. Cytotoxic activity of tumor necrosis factor is mediated by early damage of mitochondrial functions. Evidence for the involvement of mitochondrial radical generation. J Biol Chem 1992; 267(8): 5317-5323.
17. Diez-Ruiz A, Tilz GP, Zangerle R, Baier-Bitterlich G, Wachter H, Fuchs D. Soluble receptors for tumour necrosis factor in clinical laboratory diagnosis. Eur J Haematol 1995; 54(1): 1-8.
18. Brockhaus M. Soluble TNF receptor: what is the significance? Intensive Care Med 1997; 23(8): 808-9.
19. Fernandez-Real JM, Broch M, Ricart W, et al. Plasma levels of the soluble fraction of tumor necrosis factor receptor 2 and insulin resistance. Diabetes 1998; 47(11): 1757-1762.
20. Abiru S, Migita K, Maeda Y, et al. Serum cytokine and soluble cytokine receptor levels in patients with non-alcoholic steatohepatitis. Liver Int 2006; 26(1): 39-45.
21. Krawczyk K, Szczesniak P, Kumor A, et al. Adipohormones as prognostric markers in patients with nonalcoholic steatohepatitis (NASH). J Physiol Pharmacol 2009; 60 Suppl 3: 71-105.
22. Bahcecioglu IH, Yalniz M, Ataseven H, et al. Levels of serum hyaluronic acid, TNF-alpha and IL-8 in patients with nonalcoholic steatohepatitis. Hepatogastroenterology 2005; 52(65): 1549-1553.
23. Wong VW, Hui AY, Tsang SW, et al. Metabolic and adipokine profile of Chinese patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2006; 4(9): 1154-1161.
24. Ruiz AG, Casafont F, Crespo J, et al. Lipopolysaccharide-binding protein plasma levels and liver TNF-alpha gene expression in obese patients: evidence for the potential role of endotoxin in the pathogenesis of non-alcoholic steatohepatitis. Obes Surg 2007; 17(10): 1374-1380.
25. Lesmana CR, Hasan I, Budihusodo U, et al. Diagnostic value of a group of biochemical markers of liver fibrosis in patients with non-alcoholic steatohepatitis. J Dig Dis 2009; 10(3): 201-206.
26. Tokushige K, Hashimoto E, Tsuchiya N, Kaneda H, Taniai M, Shiratori K. Clinical significance of soluble TNF receptor in Japanese patients with non-alcoholic steatohepatitis. Alcohol Clin Exp Res 2005; 29(12 Suppl): 298S-303S.
27. Kugelmas M, Hill DB, Vivian B, Marsano L, McClain CJ. Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E. Hepatology 2003; 38(2): 413-4139.
28. Uysal S, Armutcu F, Aydogan T, Akin K, Ikizek M, Yigitoglu MR. Some inflammatory cytokine levels, iron metabolism and oxidant stress markers in subjects with nonalcoholic steatohepatitis. Clin Biochem 2011; 44(17-18): 1375-1409.
29. Turan B, Pfister K, Diener PA, et al. Soluble tumour necrosis factor receptors sTNFR1 and sTNFR2 are produced at sites of inflammation and are markers of arthritis activity in Behcet's disease. Scand J Rheumatol 2008; 37(2): 135-141.
30. Studnicka-Benke A, Steiner G, Petera P, Smolen JS. Tumour necrosis factor alpha and its soluble receptors parallel clinical disease and autoimmune activity in systemic lupus erythematosus. Br J Rheumatol 1996; 35(11): 1067-1074.
31. Ronnblom L, Elkon KB. Cytokines as therapeutic targets in SLE. Nat Rev Rheumatol 2010; 6(6): 339-347.
32. Smiljanovic B, Grun JR, Biesen R, et al. The multifaceted balance of TNF-alpha and type I/II interferon responses in SLE and RA: how monocytes manage the impact of cytokines. J Mol Med (Berl) 2012.(Epub ahead of print).
33. Sanchez-Alcazar JA, Schneider E, Martinez MA, et al. Tumor necrosis factor-alpha increases the steady-state reduction of cytochrome b of the mitochondrial respiratory chain in metabolically inhibited L929 cells. J Biol Chem 2000; 275(18): 13353-13361.
34. Aggarwal BB, Shishodia S, Takada Y, et al. TNF blockade: an inflammatory issue. Ernst Schering Res Found Workshop 2006(56):161-186.
35. Seckinger P, Isaaz S, Dayer JM. Purification and biologic characterization of a specific tumor necrosis factor alpha inhibitor. J Biol Chem 1989; 264(20): 11966-11973.
36. Engelmann H, Aderka D, Rubinstein M, Rotman D, Wallach D. A tumor necrosis factor-binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity. J Biol Chem 1989; 264(20): 11974-11980.
37. Crespo J, Cayon A, Fernandez-Gil P, et al. Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. Hepatology 2001; 34(6): 1158-1163.
38. Park JW, Jeong G, Kim SJ, Kim MK, Park SM. Predictors reflecting the pathological severity of non-alcoholic fatty liver disease: comprehensive study of clinical and immunohistochemical findings in younger Asian patients. J Gastroenterol Hepatol 2007; 22(4):491-497.